Interaction between α-synuclein and tau genotypes and the progression of Parkinson's disease

Journal of Parkinson's Disease

Volumn 1, Issue 3, 2011, Pages 271-276

  Huang, Yue ^a   Rowe, Dominic B ^b   Halliday, Glenda M ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

Author keywords

disease progression; genetic association; MAPT; NACP; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; TAU PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DNA POLYMORPHISM; FEMALE; GENE; GENE FREQUENCY; GENE INTERACTION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAPT GENE; NACP REP1 GENE; PARKINSON DISEASE; PILOT STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RISK FACTOR; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; ALPHA-SYNUCLEIN; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; TAU PROTEINS;

EID: 84863230106     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-2011-11027     Document Type: Article

References (36)

1. Jankovic J, & Kapadia AS (2001) Functional decline in Parkinson disease. Arch Neurol, 58, 1611-1615. (Pubitemid 32963225)
2. Lewis SJ, Foltynie T, Blackwell AD, RobbinsTW, Owen AM, & Barker RA (2005) Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry, 76, 343-348. (Pubitemid 40299121)
3. Jankovic J (2005) Progression of Parkinson disease: Are we making progress in charting the course? Arch Neurol, 62, 351-352. (Pubitemid 40349468)
4. Greffard S, Verny M, Bonnet AM, Beinis JY, Gallinari C, Meaume S, Piette F, Hauw JJ, & Duyckaerts C (2006) Motor score of the unified Parkinson disease rating scale as a good predictor of lewy body-associated neuronal loss in the substantia nigra. Arch Neurol, 63, 584-588.
5. Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, & Double KL (2005) {alpha}-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain, 128, 2654-2664 (Pubitemid 41552949)
6. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, & Brice A (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet, 364, 1169-1171. (Pubitemid 39296605)
7. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M,Waucquier N, Defebvre L, Amouyel P, Farrer M, DesteeA(2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet, 364, 1167-1169. (Pubitemid 39296604)
8. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, & Gwinn-Hardy K (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science, 302, 841. (Pubitemid 37339619)
9. Singleton A, & Gwinn-Hardy K (2004) Parkinson's disease and dementia with Lewy bodies:Adifference in dose? Lancet, 364, 1105-1107. (Pubitemid 39296587)
10. Johnson J, Hague SM, Hanson M, Gibson A, Wilson KE, Evans EW, Singleton AA, McInerney-Leo A, Nussbaum RL, Hernandez DG, Gallardo M, McKeith IG, Burn DJ, Ryu M, Hellstrom O, Ravina B, Eerola J, Perry RH, Jaros E, Tienari P, Weiser R, Gwinn-Hardy K, Morris CM, Hardy J,&Singleton AB (2004) SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies. Neurology, 63, 554-556. (Pubitemid 39031393)
11. Gispert S, Trenkwalder C, Mota-Vieira L, Kostic V, & Auburger G (2005) Failure to find alpha-synuclein gene dosage changes in 190 patients with familial Parkinson disease. Arch Neurol, 62, 96-98. (Pubitemid 40105041)
12. Pals P, Lincoln S, Manning J, Heckman M, Skipper L, Hulihan M, Van den Broeck M, De Pooter T, Cras P, Crook J, Van Broeckhoven C, & Farrer MJ (2004) alpha-Synuclein promoter confers susceptibility to Parkinson's disease. Ann Neurol, 56, 591-595. (Pubitemid 39319355)
13. Farrer M, Maraganore DM, Lockhart P, Singleton A, Lesnick TG, de Andrade M,West A, de Silva R, Hardy J,&Hernandez D(2001) alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet, 10, 1847-1851. (Pubitemid 32899100)
14. Chiba-Falek O,&NussbaumRL(2001) Effect of allelic variation at theNACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet, 10, 3101-3109. (Pubitemid 34083496)
15. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, & Lee VM (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science, 300, 636-640. (Pubitemid 36520587)
16. Mamah CE, Lesnick TG, Lincoln SJ, Strain KJ, de Andrade M, Bower JH, Ahlskog JE, Rocca WA, Farrer MJ, & Maraganore DM (2005) Interaction of alpha-synuclein and tau genotypes in Parkinson's disease. Ann Neurol, 57, 439-443. (Pubitemid 40343968)
17. Xia Y, Rohan de Silva HA, Rosi BL, Yamaoka LH, Rimmler JB, Pericak-Vance MA, Roses AD, Chen X, Masliah E, DeTeresa R, Iwai A, Sundsmo M, Thomas RG, Hofstetter CR, Gregory E, Hansen LA, Katzman R, Thal LJ, & Saitoh T (1996) Genetic studies in Alzheimer's disease with an NACP/alpha-synuclein polymorphism. Ann Neurol, 40, 207-215. (Pubitemid 26274556)
18. Higgins JJ, Golbe LI, De Biase A, Jankovic J, Factor SA, & Adler RL (2000) An extended 5 tau susceptibility haplotype in progressive supranuclear palsy. Neurology, 55, 1364-1367.
19. Mellick GD, Maraganore DM, & Silburn PA (2005) Australian data and meta-analysis lend support for alphasynuclein (NACP-Rep1) as a risk factor for Parkinson's disease. Neurosci Lett, 375, 112-116.
20. Kwok JB, Teber ET, Loy C, Hallupp M, Nicholson G, Mellick GD, Buchanan DD, Silburn PA, & Schofield PR (2004) Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann Neurol, 55, 329-334. (Pubitemid 38269584)
21. Elbaz A, Ross OA, Ioannidis JP, Soto-Ortolaza AI, Moisan F, Aasly J, Annesi G, Bozi M, Brighina L, Chartier-Harlin MC, Destee A, Ferrarese C, Ferraris A, Gibson JM, Gispert S, Hadjigeorgiou GM, Jasinska-Myga B, Klein C, Kruger R, Lambert JC, Lohmann K, van de Loo S, Loriot MA, Lynch T, Mellick GD, Mutez E, Nilsson C, Opala G, Puschmann A, Quattrone A, Sharma M, Silburn PA, Stefanis L, Uitti RJ, Valente EM, Vilarino-Guell C, Wirdefeldt K, Wszolek ZK, Xiromerisiou G, Maraganore DM, & Farrer MJ (2010) Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann Neurol, 69 778-792.
22. Cosentino S, Scarmeas N, Helzner E, Glymour MM, Brandt J, Albert M, Blacker D,&Stern Y (2008) APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology, 70, 1842-1849. (Pubitemid 351653957)
23. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, & Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24, 197-211. (Pubitemid 36007810)
24. Waragai M, Sekiyama K, SekigawaA, TakamatsuY, Fujita M, &HashimotoM(2010) alpha-Synuclein and DJ-1 as Potential Biological Fluid Biomarkers for Parkinson's Disease. Int J Mol Sci, 11, 4257-4266.
25. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, & Zhang J (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain, 133, 713-726.
26. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, & Schlossmacher MG (2011) alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study. Lancet Neurol, 10, 230-240.
27. Braak H, Rub U, & Del Tredici K (2006) Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci, 248, 255-258. (Pubitemid 44647283)
28. Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJ, Brown J, Ban M, Spillantini MG, Compston A, Burn DJ, Chinnery PF, Barker RA, & Sawcer SJ (2007) Tau and alphasynuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol, 62, 145-153. (Pubitemid 47546500)
29. Jellinger KA (2011) Interaction between alpha-synuclein and tau in Parkinson's disease comment on Wills et al.: Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010; 225 : 210-218.
30. Exp Neurol, 227, 13-18.
31. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, & LaFerla FM (2010) Synergistic Interactions between Abeta, tau, and alpha-synuclein: Acceleration of neuropathology and cognitive decline. J Neurosci, 30, 7281-7289.
32. Rajput AH, Voll A, Rajput ML, Robinson CA, & Rajput A (2009) Course in Parkinson disease subtypes: A 39-year clinicopathologic study. Neurology, 73, 206-212.
33. Halliday G (2008) Clarifying the pathological progression of Parkinson's disease. Acta Neuropathol, 115, 377-378.
34. Selikhova M,Williams DR, Kempster PA, Holton JL, Revesz T, & Lees AJ (2009) A clinico-pathological study of subtypes in Parkinson's disease. Brain, 132, 2947-2957.
35. Pankratz N,Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, Doheny KF, Gusella JF, Nichols WC, Foroud T, & Myers RH (2009) Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet, 124, 593-605.
36. Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, Simon-Sanchez J, Schulte C, Lesage S, Sveinbjornsdottir S, Arepalli S, Barker R, Ben-ShlomoY, Berendse HW, Berg D, Bhatia K, de Bie RMA, Biffi A, Bloem B, Bochdanovits Z, Bonin M, Bras JM, Brockmann K, Brooks J, Burn DJ, Charlesworth G, Chen HL, Chinnery PF, Chong S, Clarke CE, Cookson MR, Cooper JM, Corvol JC, Counsell C, Damier P, Dartigues JF, Deloukas P, Deuschl G, Dexter DT, van Dijk KD, Dillman A, Durif F, Durr A, Edkins S, Evans JR, Foltynie T, Gao JJ, Gardner M, Gibbs JR, Goate A, Gray E, Guerreiro R, Gustafsson O, Harris C, van Hilten JJ, Hofman A, Hollenbeck A, Holton J, Hu M, Huang XM, Huber H, Hudson G, Hunt SE, Huttenlocher J, Illig T, Jonsson PV, Lambert JC, Langford C, Lees A, Lichtner P, Limousin P, Lopez G, Lorenz D, McNeill A, Moorby C, Moore M, Morris HR, Morrison KE, Mudanohwo E, O'Sullivan SS, Pearson J, Perlmutter JS, Petursson H, Pollak P, Post B, Potter S, Ravina B, Revesz T, Riess O, Rivadeneira F, Rizzu P, Ryten M, Sawcer S, Schapira A, Scheffer H, Shaw K, Shoulson I, Sidransky E, Smith C, Spencer CCA, Stefansson H, Stockton JD, Strange A, Talbot K, Tanner CM, Tashakkori-Ghanbaria A, Tison F, Trabzuni D, Traynor BJ, Uitterlinden AG, Velseboer D, Vidailhet M,Walker R, van deWarrenburgB, Wickremaratchi M, Williams N, Williams-Gray CH, Winder-Rhodes S, Stefansson K, Martinez M, Hardy J, Heutink P, Brice A, Gasser T, Singleton AB,WoodNW, Consort IPDG, & Consor WTCC (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association studies. Lancet, 377, 641-649.